Drug companies doing business abroad—and who isn't?—face a special risk of running afoul of stepped-up enforcement of anticorruption laws. Travel alert: When in Rome, don't! Jun 1, 2007 By:R. Christopher Cook, Jonathan B. Leiken
Compliance requires overcoming cultural barriers. To start with, in some countries the taboo against bribery is not as strong as it is here.
Pharma tends not to treat relationships with foreign doctors as cautiously as it does those with US physicians. But watch out: Misconduct on the part of your international employees could get kicked back onto your plate. May 1, 2006 By:R. Christopher Cook, Jesse A. Witten
Criminal penalties for violating the Foreign Corrupt Practices Act can be substantial. Businesses found guilty may be fined upwards of $2.5 million for each offense, or twice the amount gained as a result of the violation.